Trials / Active Not Recruiting
Active Not RecruitingNCT07078695
A Trial of SHR-1139 in Healthy Volunteers
A Phase 1, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Subcutaneous/Intravenous Administered SHR-1139 in Healthy Participants
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1139 Injection | Single dose of SHR-1139 given subcutaneously (dose level 1 ) |
| DRUG | SHR-1139 Injection | Single dose of SHR-1139 given subcutaneously (dose level 2 ) |
| DRUG | SHR-1139 Injection | Single dose of SHR-1139 given intravenously (dose level 3) |
Timeline
- Start date
- 2025-08-19
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2025-07-22
- Last updated
- 2026-03-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07078695. Inclusion in this directory is not an endorsement.